Meeting
2021 ASCO Annual Meeting
Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström macroglobulinemia (WM): Matching-adjusted indirect comparisons.
Authors
Jorge J. Castillo
Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Jorge J. Castillo , Keri Yang , Rongzhe Liu , Yu Wang , Aileen Cohen , Todd M. Zimmerman , Qian Zhao , Xin Gao , Boxiong Tang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7559)
DOI
10.1200/JCO.2021.39.15_suppl.7559
Abstract #
7559
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
First Author: Christopher Flowers
Poster
2023 ASCO Annual Meeting
Preliminary data of a phase 1b/2 study of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).
First Author: Sikander Ailawadhi
Poster
2021 ASCO Annual Meeting
Randomized, double-blind, placebo-controlled phase 3 study of ibrutinib plus rituximab in patients with previously untreated marginal zone lymphoma (MZL).
First Author: Ariela Noy